Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments

International Journal of Bipolar Disorders

Volumn 3, Issue 1, 2015, Pages

  Frye, Mark A ^a   Amchin, Jess ^b   Bauer, Michael ^c   Adler, Caleb ^d   Yang, Ronghua ^b   Ketter, Terence A ^e  

^a MAYO CLINIC   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY OF CINCINNATI   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

Armodafinil; Bipolar I disorder; Major depressive episode

Indexed keywords

ARMODAFINIL; PLACEBO;

16 ITEM QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY CLINICIAN RATED; ADULT; ARTICLE; ASSESSMENT OF HUMANS; BIPOLAR DEPRESSION; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPOMANIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; TREATMENT OUTCOME; YOUNG MANIA RATING SCALE;

EID: 85041672973     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/s40345-015-0034-0     Document Type: Article

References (24)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, text revision: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association; 2000.
2. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307.
3. Bauer MS, Kirk GF, Gavin C, Williford WO. Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. J Affect Disord. 2001;65:231–41.
4. Calabrese JR, Hirschfeld RM, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry. 2004;65:1499–504.
5. Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71:1363–70.
6. Calabrese JR, Frye MA, Yang R, Ketter TA, for the Armodafinil Treatment Trial Study Network. Efficacy and safety of armodafinil for the adjunctive treatment of major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled; multicenter trial. J Clin Psychiatry. 2014;75:1054–61.
7. First MB, Williams JBW, Spitzer RL, Gibbon M. Structured clinical interview for DSM-IV-TR axis I disorders, clinical trials version (SCID-CT). New York: Biometrics Research, New York State Psychiatric Institute; 2007.
8. Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE, Walden J, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164:1242–9.
9. Hamilton Anxiety Rating Scale (HAM-A). 2011; UF MedConsults. Available at: http://dcf.psychiatry.ufl.edu/files/2011/05/HAMILTON-ANXIETY.pdf. Accessed: July 20, 2015.
10. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–7.
11. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–27.
12. Ketter TA, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J Affect Disord. 2015;181:87–91.
13. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9:531–5.
14. Latuda [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc., 2013.
15. Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol. 2012;32:470–8.
16. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RMA, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543–52.
17. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241–51.
18. Nuvigil [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc., 2013.
19. Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, Fisher P, Zelazny J, Burke A, Oquendo M, Mann J. Columbia-Suicide Severity Rating Scale (C-SSRS) Since Last Visit. 2009; Columbia University Medical Center. Available at: http://www.cssrs.columbia.edu/docs/C-SSRS_1-14-09-Since_Last_Visit_Clinical.pdf. Accessed: July 20, 2015.
20. Rush AJ, Carmody T, Reimitz PE. The inventory of depressive symptomatology (IDS): clinician (C-IDS) and self-report (IDS-SR) ratings of depressive symptoms. Int J Meth Psychiatr Res. 2000;9:45–59.
21. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–83.
22. Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vandenburg DG, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:1413–22.
23. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28:13–20.
24. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35.